AA-FENO-SUPER TABLET
País: Canadà
Idioma: anglès
Font: Health Canada
Fitxa tècnica
(SPC)
13-08-2021
Alguns documents d’aquest producte actualment no estan disponibles, podeu enviar una sol·licitud al nostre servei d’atenció al client i us ho notificarem tan bon punt puguem obtenir-los.
Enviar sol.licitud.
Enviar sol.licitud.
ingredients actius:
FENOFIBRATE
Disponible des:
AA PHARMA INC
Codi ATC:
C10AB05
Designació comuna internacional (DCI):
FENOFIBRATE
Dosis:
200MG
formulario farmacéutico:
TABLET
Composición:
FENOFIBRATE 200MG
Vía de administración:
ORAL
Unidades en paquete:
100
tipo de receta:
Prescription
Área terapéutica:
FRIBIC ACID DERIVATIVES
Resumen del producto:
Active ingredient group (AIG) number: 0118895001; AHFS:
Estat d'Autorització:
APPROVED
Data d'autorització:
2021-08-17
Fitxa tècnica
Page 1 of 38
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AA-FENO-SUPER
FENOFIBRATE TABLETS
HOUSE STANDARD
100 MG, 160 MG AND 200 MG
LIPID METABOLISM REGULATOR
AA PHARMA INC.
DATE OF REVISION:
1165 CREDITSTONE ROAD UNIT #1
AUGUST 13, 2021
VAUGHAN, ONTARIO
L4K 4N7
CONTROL # 254380
Page 2 of 38
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................................
8
DRUG INTERACTIONS
........................................................................................................................................
12
DOSAGE AND ADMINISTRATION
....................................................................................................................
16
OVERDOSAGE
......................................................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................................
17
STORAGE AND STABILITY
................................................................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.....................................
Llegiu el document complet
